Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing large cell lymphoma.

C Gisselbrecht1, N Mounier

  • 1Institute for Hematology, Hôpital Saint Louis, Paris, France. christian.gisselbrecht@sls.ap-hop-paris.fr

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Blood·2017
Same author

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

Bone marrow transplantation·2016
Same author

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Bone marrow transplantation·2016
Same author

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Bone marrow transplantation·2015
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Rituximab improves chemotherapy, but outcomes are poor for high-risk patients. Further research is needed to determine if rituximab enhances intensive treatments and how molecular profiling can guide novel agent use.

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Standard chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) have been improved by the addition of rituximab.
  • However, patients with adverse risk factors still face poor prognoses despite these advancements.

Purpose of the Study:

  • To evaluate if rituximab enhances the efficacy of more intensive treatment protocols.
  • To explore the utility of molecular profiling in guiding the introduction of novel therapeutic agents.

Main Methods:

  • This study investigates the impact of rituximab on intensive chemotherapy regimens.
  • It also examines the role of molecular profiling in personalized treatment strategies.

Main Results:

Related Experiment Videos

  • Rituximab has demonstrated significant improvements in standard chemotherapy efficacy.
  • The study highlights the unmet need for improved outcomes in high-risk patient populations.

Conclusions:

  • Further investigation is required to ascertain rituximab's benefit in intensive treatments.
  • Molecular profiling holds promise for guiding the selection of novel agents to improve patient outcomes.